The present disclosure provides beverages displaying an edible printed image and a method of preparing such beverages.

The present disclosure provides beverages displaying an edible printed image and a method of preparing such beverages.

Provided is a highly safe metastasis inhibitor of tumor cells that can be substituted for a conventionally known metastasis inhibitor of tumor cells. A compound represented by Chemical Formula 1A or Chemical Formula 1B described in the description is used as an aspartic acid synthesis inhibitor in tumor cells, a spheroid formation inhibitor of tumor cells, or an action enhancer of glycolysis inhibitors. These inhibitors have a function as a highly potent metastasis inhibitor of tumor cells.

Provided is a highly safe metastasis inhibitor of tumor cells that can be substituted for a conventionally known metastasis inhibitor of tumor cells. A compound represented by Chemical Formula 1A or Chemical Formula 1B described in the description is used as an aspartic acid synthesis inhibitor in tumor cells, a spheroid formation inhibitor of tumor cells, or an action enhancer of glycolysis inhibitors. These inhibitors have a function as a highly potent metastasis inhibitor of tumor cells.

Disclosed is a composition for ameliorating, preventing or treating an autoimmune skin disease, containing a Musan box (Sphallerocarpus gracilis) extract or a fraction thereof as an active ingredient.

The present invention aims to provide a milk protein-containing granular composition which exhibits good dispersibility in a solvent such as water and of which discoloration over time is suppressed, a method of producing the same, and a method of improving the dispersibility of a milk protein-containing granular composition. The present invention relates to a milk protein-containing granular composition containing a milk protein and hydroxypropyl cellulose, and the like.

This application provides an areca nut-flavored product, containing an arecoline salt. Because an arecoline salt is used in the product, a user absorbs arecoline when consuming the product, and an effect similar to chewing areca nuts is produced, with relatively little irritation.

This application provides an areca nut-flavored product, containing an arecoline salt. Because an arecoline salt is used in the product, a user absorbs arecoline when consuming the product, and an effect similar to chewing areca nuts is produced, with relatively little irritation.

Alcoholic beverage-substitutes such as a beer-substitute, a wine-substitute, a cider-substitute, an alcopop-substitute or a spirit-substitute beverage, comprising a base liquid (e.g., a base beverage) and a 2-aminoindan derivative such as defined by Formula I in the specification are disclosed.

Embodiments of the present invention are directed to ingredients, formulations, methods of manufacture and use of an oral rehydration solution (“ORS”) in the prevention and treatment of dehydration in humans. More specifically, invention embodiments relate to flavored electrolyte drink mixtures that relieve the dehydrating effects caused by travel, exercise, over-indulgence of toxic substances, and various illnesses in individual subjects. An ORS embodiment of the present invention restores fluid and electrolyte balance in humans as fast and as effectively as IV therapy, and thereby reduces the incidence of dehydration in human populations as well as rehydrating individuals in circumstances where IV therapy is not practical or wanted. The disclosed ORS therapies and packs may be used in conjunction with IV therapy as a multi-part strategy to allow hospitals to lower patient re-admission rates, lower staffing needs, give outpatient self-therapy to treatments prescribed outside of the hospital environment, and thus lower treatment and process costs while not reducing system or treatment efficacy.